More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
Researchers found that cancer risk in premenopausal women with fatty breasts at initial imaging nearly doubled if an increase in density was observed during their second and third mammograms.
The ambitious project seeks to exponentially increase new data within the U.K. Biobank, a prominent large-scale biomedical database and research resource.
A machine learning system has come along that needs no human labeling of data for training yet matches radiologists at classifying diseases on chest X-rays—including some that the model was not specifically taught to detect.
